Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Pancreatic Cancer With Abraxane

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Metastatic pancreatic carcinoma~2. Age \> 18 years~3. Signed Informed Consent~4. Normal hepatic, renal and Bone Marrow functions~Exclusion Criteria:~1. Pregnant and lactating females 2. Previous treatment for metastatic pancreatic disease 3. Known hypersensitivity to nab-paclitaxel 4. Neutrophils \< 1,5 x 10\^9/L~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abraxane + Gemcitabine (Type: None): Abraxane 125mg by intravenous( IV) infusion + Gemcitabine 1000mg by intravenous on Days 1, 8, 15 of every 21 day cycle until progression

Based on this trial design, predict the completion outcome and termination type (if applicable).